The number of COVID-19 vaccination doses administered in European Union rose to 941314159 as of Oct 27 2023. This dataset includes a chart with historical data for European Union Coronavirus Vaccination Total.

This dataset covers all patients and vaccinations administered or planned for Covid-19, in or funded by the NHS.

This dataset covers all patients and vaccinations administered or planned for Covid-19, in or funded by the NHS. Dataset is a de-identified record-level data of people who have received a vaccination for COVID-19, including details of the type of vaccine and date of vaccination.

Context

The downloadable data file contains information on COVID-19 vaccination in the EU/EEA.

The data are presented in the Vaccine Tracker and collected through The European Surveillance System (TESSy). EU/EEA Member States are requested to report basic indicators (number of vaccine doses distributed by manufacturers, number of first, second and unspecified doses administered) and data by target groups at national level twice a week (every Tuesday and Friday).

Data are subject to retrospective corrections; corrected datasets are released as soon as the processing of updated national data has been completed.

Source

• https://www.ecdc.europa.eu/en/publications-data/data-covid-19-vaccination-eu-eea

Einstellungen zur Impfung gegen Covid-19. Themen: präferierter Impfzeitpunkt; Wichtigkeit der folgenden Gründe im Hinblick auf die Entscheidung, sich impfen zu lassen: Impfstoff wird bei der Beendigung der Pandemie helfen, Impfstoff wird den/die Befragte/n vor Covid-19 schützen, Impfstoff wird Verwandte und andere vor COVID-19 schützen, Impfstoff wird wieder ein normaleres Berufsleben ermöglichen, Impfstoff wird das Reisen ermöglichen, Impfstoff wird Treffen mit Familie und Freunden ermöglichen, Impfstoff wird Restaurantbesuche und andere Aktivitäten wieder ermöglichen; Wichtigkeit der folgenden Gründe im Hinblick auf die Entscheidung, sich nicht impfen zu lassen: Pandemie wird bald vorbei sein, persönliches Infektionsrisiko ist sehr gering, Risiko durch COVID-19 ist allgemein übertrieben, Sorgen über die Nebenwirkungen von COVID-19-Impfstoffen, Impfstoffe sind noch nicht ausreichend getestet, Impfstoffe sind unwirksam, generelle Ablehnung von Impfungen; Faktoren, die die persönliche Impfbereitschaft erhöhen würden: mehr geimpfte Menschen im Umfeld, viele erfolgreich geimpfte Menschen ohne gravierende Nebenwirkungen, Menschen, die die Impfung empfehlen, sind selbst geimpft, Empfehlung des eigenen Arztes, Entwicklung der Impfstoffe in der Europäischen Union, vollständige Klarheit über Entwicklung, Testung und Zulassung der Impfstoffe, starker Wunsch nach einer Impfung bzw. Befragte/r ist bereits geimpft, keine Impfung geplant; Einstellung zu den folgenden Aussagen zu den Impfstoffen: Vorteile überwiegen mögliche Risiken, in der EU zugelassene Impfstoffe sind sicher, zu schnelle Entwicklung, Testung und Zulassung der Impfstoffe, um sicher zu sein, noch unbekannte potentielle Langzeit-Nebenwirkungen, Impfung ist die einzige Möglichkeit zur Beendigung der Pandemie, kein Verständnis für Impfgegner, Ausrottung ernsthafter Krankheiten durch Impfung; Einstellung zu den folgenden Aussagen: Ansteckung kann auch ohne Impfung vermieden werden, mangelnde Transparenz öffentlicher Behörden in Bezug auf die Corona-Impfstoffe, Impfung gegen COVID-19 ist Bürgerpflicht, Impfung sollte verpflichtend sein, Europäische Union spielt wesentliche Rolle bei der Versorgung des eigenen Landes mit Impfstoff; vertrauenswürdigste Institutionen oder Personen im Hinblick auf die Bereitstellung von Informationen über Corona-Impfstoffe; Interesse an zusätzlichen Informationen über die folgenden Aspekte: Entwicklung, Testung und Zulassung von COVID-19-Impfstoffen, Sicherheit von COVID-19- Impfstoffen, Effektivität von COVID-19-Impfstoffen; Zufriedenheit mit der Umsetzung der Impfstrategie durch: nationale Regierung, EU; Anwendbarkeit der folgenden Aussagen: Befragte/r kennt Menschen mit positivem Corona-Testergebnis, Befragte/r kennt Menschen mit Corona-Erkrankung, Befragte/r hatte positives Corona-Testergebnis, Befragte/r war an Corona erkrankt, Befragte/r fürchtet Ansteckung in der Zukunft; Impfung des/der Befragten als: Kind, Erwachsener; Einstellung zu Impfstoffen im allgemeinen: sind sicher, sind wirksam. Demographie: Alter; Geschlecht; Staatsangehörigkeit; Alter bei Beendigung der Ausbildung; Beruf; berufliche Stellung; Urbanisierungsgrad; Haushaltszusammensetzung und Haushaltsgröße; Region. Zusätzlich verkodet wurde: Befragten-ID; Land; für das Interview genutztes Gerät; Nationengruppe; Gewichtungsfaktor. Attitudes on vaccination against Covid-19. Topics: preferred time for getting vaccinated; importance of each of the following issues with regard to getting vaccinated: vaccine will help to end the pandemic, vaccine will protect respondent from getting Covid-19, vaccine will protect relatives and others from getting Covid-19, vaccine will make it possible to resume a more normal professional life, vaccine will make it possible to travel, vaccine will make it possible to meet family and friends, vaccine will make it possible to go to restaurants, cinemas etc.; importance of each of the following issues with regard to not getting vaccinated: pandemic will be over soon, personal risk of being infected is very low, risk posed by Covid-19 in general is exaggerated, worries about side effects of Covid-19 vaccines, vaccines have not been sufficiently tested yet, vaccines are ineffective, against vaccines in general; factors to increase personal willingness of getting vaccinated: more people around doing it, more people have already been vaccinated and we see that there are no major side-effects, people that recommend the vaccines are vaccinated themselves, doctor recommends respondent to do so, vaccines are developed in the European Union, full clarity on how vaccines are being developed, tested and authorized, respondent is very eager to get vaccinated or is already vaccinated, won’t get vaccinated anyway; attitude towards the following statements on the vaccines: benefits outweigh possible risks, vaccines authorised in the European Union are safe, vaccines are being developed, tested and authorised too quickly to be safe, vaccines could have long term side-effects that we do not know yet, a vaccine is the only way to end the pandemic, no understanding why people are reluctant to get vaccinated, serious diseases have disappeared thanks to vaccines; attitude towards the following statements: one can avoid being infected without being vaccinated, public authorities are not sufficiently transparent about COVID-19 vaccines, getting vaccinated against COVID-19 is a civic duty, vaccination should be compulsory, European Union is playing a key role in ensuring access to COVID-19 vaccines in the own country; most trustworthy institutions or persons regarding the provision of information about COVID-19 vaccines; interest in additional information about the following aspects: development, testing, and authorization of COVID-19 vaccines, safety of COVID-19 vaccines, effectiveness of COVID-19 vaccines; satisfaction with the handling of the vaccination strategy by: national government, EU; applicability of the following statements: respondent knows people who have tested positive to COVID-19, respondent knows people who have been ill because of COVID-19, respondent has tested positive to COVID-19, respondent has been ill because of COVID-19, respondent fears to be infected in the future; vaccination of respondent: as a child, as an adult; attitude towards vaccines in general: are safe, are effective. Demography: age; sex; nationality; age at end of education; occupation; professional position; type of community; household composition and household size; region. Additionally coded was: respondent ID; country; device used for interview; nation group; weighting factor.

Context

All about an attempt to end the pandemic across the globe with the help of vaccinations for COVID-19. It is important to track and understand the effort that is in progress across the globe to administer doses of vaccinations. There could be many sources of information. This is one of the sources from Bloomberg that is captured and presented here. Additionally, I have tried to include the GDP per capita per country from Wiki so that we can see how that is influencing the vaccination progress.

Content

There are two files. a) Latest Global Covid-19 Vaccine tracker of all the countries and regions in the World as of September 11, 2021 b) GDP information per capita per country

Attribute Information (COVID19 vaccination Tracker file)

• Countries and regions - Name of countries
• Doses administered - Number of vaccine doses administered
• Enough for % of people - Number of vaccine doses administered as a % of population
• Percentage of population with 1+ dose - Percentage of the population vaccinated with at least 1+ dose
• Percentage of the population fully vaccinated - Percentage of the population fully vaccinated
• Daily rate of doses administered - Daily rate of doses administered

Attribute Information (for GDP file per country per capita)

• Country
• Subregion (Western Europe, Northern Europe etc.)
• Region (Europe, Asia etc.)
• GDP estimate $ as per IMF
• Year for IMF
• GDP estimate $ as per UN
• Year for UN
• GDP estimate $ as per World Bank
• Year for World Bank

Source

URL1: https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/ URL2: https://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nominal)_per_capita

Inspiration

The path to immunity and hope to get back to normalcy by tracking and analyzing the latest updates on vaccinations across the globe. As we gear up to end the pandemic, the vaccination tracker can help us answer the following questions.

• What are the Top N countries/regions where vaccinations are administered?
• What are the Top N countries/regions with fully vaccinated people?
• What are the Top N countries/regions with at least 1+ doses administered?
• What is the access to vaccines - by least wealthy and most wealthy countries? (based on GDP per capita per country data)
• What is the average daily rate of the dose administered? Which countries are Top N and Bottom N? Which countries are above and below the World average? and many more...

Thank you for reading.

Please give your feedback/upvote/comments if you find this useful and download.

The Aotearoa New Zealand (NZ) Cervical Screening Programme (NCSP) commenced in 1990. The NCSP has failed to equally reach its eligible population, consequently, cervical cancer rates by ethnicity are inequitable. In 2008, the Aotearoa NZ human papillomavirus (HPV) vaccination programme was introduced. The aim of this study was to determine the impact of HPV vaccination on the occurrence of high-grade cervical abnormalities and cancer in the cohort of people who were eligible for vaccination and underwent cervical screening. Data on the NCSP register were matched to the national vaccination register and the incidence of detected cervical abnormalities by vaccination status, ethnicity, birth cohort, and year of vaccination was determined. HPV vaccination was associated with a marked reduction in cervical cancer (hazard ratio [HR] 0.32) and adenocarcinoma in situ (HR 0.26). Vaccinated people were also less likely to experience a high-grade squamous cervical cytology (HR 0.75) or histology (HR 0.71). We observed equitable access to vaccination and protection against HSIL among Māori, Pacific, and European people. This data is important evidence of the real-world effectiveness of HPV vaccination in Aotearoa NZ. Vaccination improves outcomes equitably for Māori, Pacific peoples, and NZ Europeans. Increased vaccination rates are required for cervical cancer elimination.

The National Rabies Management Program conducts ORV operations in many US states. State summaries, maps, and statistics for oral rabies vaccine distribution can be accessed through this database. Rabies is caused by a virus that infects the central nervous system in mammals. It is almost always transmitted through the bite of a rabid animal. The majority of rabies cases in the United States occur in wildlife including raccoons, skunks, foxes and bats. Rabies is invariably fatal, however, effective vaccines are available to protect people, pets and livestock. The National Rabies Management Program was established in recognition of the changing scope of rabies. The goal of the program is to prevent the further spread of wildlife rabies and eventually eliminate terrestrial rabies in the United States through an integrated program that involves the use of oral rabies vaccination targeting wild animals. Since, 1995, Wildlife Services (WS) has been working cooperatively with local, State, and Federal governments, universities and other partners to address this public health problem by distributing oral rabies vaccination (ORV) baits in targeted areas. This cooperative program targets the raccoon variant, canine variant in coyotes and a unique variant of gray fox rabies Resources in this dataset:Resource Title: ORV Information by State. File Name: Web Page, url: https://www.aphis.usda.gov/aphis/ourfocus/wildlifedamage/programs/nrmp/orv-information-by-state Links with resources including shapefiles, maps, and reports.

Introduction: In 2021, the European Medicines Agency supported the “Covid Vaccine Monitor (CVM),” an active surveillance project spanning 13 European countries aimed at monitoring the safety of COVID-19 vaccines in general and special populations (i.e., pregnant/breastfeeding women, children/adolescents, immunocompromised people, and people with a history of allergies or previous SARS-CoV-2 infection). Italy participated in this project as a large multidisciplinary network called the “ilmiovaccinoCOVID19 collaborating group.”Methods: The study aimed to describe the experience of the Italian network “ilmiovaccinoCOVID19 collaborating group” in the CVM context from June 2021 to February 2023. Comprising about 30 partners, the network aimed to facilitate vaccinee recruitment. Participants completed baseline and follow-up questionnaires within 48 h from vaccination over a 6-month period. Analyses focused on those who completed both the baseline and the first follow-up questionnaire (Q1), exploring temporal trends, vaccination campaign correlation, and loss to follow-up. Characteristics of recruited vaccinees and vaccinee-reported adverse drug reactions (ADRs) were compared with passive surveillance data in Italy.Results: From June 2021 to November 2022, 22,384,663 first doses and 38,207,452 booster doses of COVID-19 vaccines were administered in Italy. Simultaneously, the study enrolled 1,229 and 2,707 participants for the first and booster doses, respectively. Of these, 829 and 1,879 vaccinees, respectively, completed both baseline and at least Q1 and were included in the analyses, with a significant proportion of them (57.8%/34.3%) belonging to special cohorts. Most vaccinees included in the analyses were women. Comirnaty® (69%) and Spikevax® (29%) were the most frequently administered vaccines. ADR rates following Comirnaty® and Spikevax® were higher after the second dose, particularly following Spikevax®. Serious ADRs were infrequent. Differences were observed in ADR characteristics between CVM and Italian passive surveillance.Conclusion: This study confirmed the favorable safety profile of COVID-19 vaccines, with findings consistent with pivotal clinical trials of COVID-19 vaccines, although different proportions of serious ADRs compared to spontaneous reporting were observed. Continuous evaluation through cohort event monitoring studies provides real-time insights crucial for regulatory responses. Strengthening infrastructure and implementing early monitoring strategies are essential to enhance vaccine safety assessment and prepare for future pandemics.

Objectives: Young adults are essential to the effective mitigation of the novel coronavirus (SARS-CoV-2/COVID-19) given their tendency toward greater frequency of social interactions. Little is known about vaccine willingness during pandemics in European populations. This study examined young people’s attitudes toward COVID-19 vaccines in Fall 2020.Methods: Data came from an ongoing longitudinal study’s online COVID-19-focused supplement among young adults aged 22 in Zurich, Switzerland (N = 499) in September 2020. Logistic regressions examined young adults’ likelihood of participating in COVID-19 immunization programs.Results: Approximately half of respondents reported being unlikely to get vaccinated against COVID-19. Compared to males, females were more likely to oppose COVID-19 vaccination (p < 0.05). In multivariate models, Sri Lankan maternal background and higher socioeconomic status were associated with a greater likelihood of getting vaccinated against COVID-19 (p < 0.05). Respondents were more likely to report a willingness to get vaccinated against COVID-19 when they perceived 1) an effective government response (p < 0.05) and 2) their information sources to be objective (p < 0.05).Conclusion: This study communicates aspects important to the development of targeted information campaigns to promote engagement in COVID-19 immunization efforts.

The mosquito-borne West Nile virus (WNV) causes human and animal disease with outbreaks in several parts of the world including North America, the Mediterranean countries, Central and East Europe, the Middle East, and Africa. Particularly in elderly people and individuals with an impaired immune system, infection with WNV can progress into a serious neuroinvasive disease. Currently, no treatment or vaccine is available to protect humans against infection or disease. The goal of this study was to develop a WNV-vaccine that is safe to use in these high-risk human target populations. We performed a vaccine efficacy study in non-human primates using the contemporary, pathogenic European WNV genotype 1a challenge strain, WNV-Ita09. Two vaccine strategies were evaluated in rhesus macaques (Macaca mulatta) using recombinant soluble WNV envelope (E) ectodomain adjuvanted with Matrix-M, either with or without DNA priming. The DNA priming immunization was performed with WNV-DermaVir nanoparticles. Both vaccination strategies successfully induced humoral and cellular immune responses that completely protected the macaques against the development of viremia. In addition, the vaccine was well tolerated by all animals. Overall, The WNV E protein adjuvanted with Matrix-M is a promising vaccine candidate for a non-infectious WNV vaccine for use in humans, including at-risk populations.

Given crises of public confidence in certain childhood vaccination regimes both in the United Kingdom and West Africa, this study used the lens of vaccination to explore emerging science-society relations in European and African settings which have conventionally been theorised very differently. Focusing on the case of measles, mumps and rubella (MMR) vaccination in Brighton, England and on the intersection of routine vaccination with Medical Research Council (MRC) research on a major pneumococcal vaccine trial in the Upper River Division of Gambia, this project used ethnographic and survey methods to explore parents' own perspectives and decision-making processes around vaccination and research participation.

It aimed to assess how different parents' concerns are shaped by conceptual frameworks and knowledges around disease and immunity, and broader experiences of public health care and science, and how different people consider 'trade-offs' between social and individual benefits and risks. It also explored how vaccine scientists and public health professionals conceive of public perspectives around vaccination, and how 'frontline' staff mediate professional and public views. The study drew on perspectives from medical anthropology and the sociology of science, and used a combination of research methods. Only data from the quantitative phase of the research is included in this dataset.

The quantitative research was conducted as follows. Mothers and fathers of a selected sample of children in the Brighton and Hove Primary Care Trust (PCT) area were asked to complete a questionnaire covering their views on the risks associated with the MMR vaccination, along with demographic information and child health, and this was linked to information from the PCT child health database. For the Gambian survey, a sample of mothers were given a questionnaire on the health of their children. For further details of sampling and methodology used at both locations, see documentation.